Skip to main content

Table1 Clinical characteristics of patients and controls

From: Transcriptomic profiling of high- and low-spiking regions reveals novel epileptogenic mechanisms in focal cortical dysplasia type II patients

S. no. Patient ID Sample ID Age (years) Sex Pathology/COD ECOG MRI MEG PET Age at onset Frequency of seizure Anti-epileptic drugs
1 F1 E018 13 F FCD TYPE IIB 1 0 ND 0 6 years 3–4/day CLM, LVM, SV
2 F1 E115 4 0 ND 0
3 F2 E075 18 M FCD TYPE IIB 1 0 1 0 1.5 years 1–2/day LMG, CLM, LVM,
TPM
4 F2 E028 3 1 0 1
5 F3 Sample-E1 24 F FCD TYPE IIA 5 0 0 0 8 months 1–2/day CLM, LCS,
OXCBZ, SV
6 F4 E019 6 M FCD TYPE IIA 1 0 0 1 3 years 6–7/day LVM, CBZ, CLM
7 F4 E006 5 1 0 1
8 F5 E273 5 F FCD TYPE IIB 1 0 1 0 2 months 1–2/day CLM, OXCBZ
9 F5 E135 4 1 1 1
10 F6 E077 14 M FCD TYPE IIA 1 1 ND 0 9 years 2–3/month CLM, LVM, PHY
11 F6 E045 3 1 ND 1
12 F7 E070 12 F FCD TYPE IIB 1 0 0 0 5 years 5–7/day LVM, OXCBZ,
CLM
13 F7 E084 5 1 0 1
14 F8 E460 19 F FCD TYPE IIA 1 0 1 0 9 months 2–3/day LMG, CLM
15 F8 E536 5 0 1 1
16 F9 E578 22 F FCD TYPE IIA 1 0 1 0 6 years 3–4/day LVM, CBZ, TPM,
CLM
17 F9 E593 3 1 1 0
18 A1 A1 18 F Pelvic injury NA NA NA NA NA NA NA
19 A2 A2 25 M Abdominal injury NA NA NA NA NA NA NA
20 A3 A3 22 M Pelvic and limb injury NA NA NA NA NA NA NA
21 A4 A4 37 M Abdominal injury NA NA NA NA NA NA NA
22 A5 A5 32 M Abdominal injuries NA NA NA NA NA NA NA
23 A6 A6 20 M Hanging NA NA NA NA NA NA NA
24 A7 A7 65 F Myocardial infarction NA NA NA NA NA NA NA
25 A8 A8 16 F Pelvic and limb injury NA NA NA NA NA NA NA
  1. COD  cause of death, ND  not done, 0  Negative, 1  Positive, CBZ carbamazepine, OXCBZ  oxcarbazepine, CLM  clobazam, SV  sodium valproate, PHE  phenytoin, LVM  leveteracetam, LMG  lamotrigine, TP  topiramate